Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 25-31

  Bartsch, R ^a   Berghoff, A ^a   Pluschnig, U ^a   Bago Horvath, Z ^a   Dubsky, P ^a   Rottenfusser, A ^a   Devries, C ^a   Rudas, M ^a   Fitzal, F ^a   Dieckmann, K ^a   Mader, R M ^a   Gnant, M ^a   Zielinski, C C ^a   Steger, G G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

brain metastases; breast cancer; HER2 positive disease; lapatinib; trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 84855348673     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.531     Document Type: Article

References (39)

1. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomta T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295: 2483-2491 (Pubitemid 43854963)
2. Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG (2009) Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 9: 367
3. Bartsch R, Rottenfusser A, Wenzel C, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG (2007) Trastuzumab prolongs overall survival in patients with brain metastases from HER2 positive breast cancer. J Neurooncol 85: 311-317 (Pubitemid 350142522)
4. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972-2977 (Pubitemid 36676250)
5. Bindal RK, Samaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79: 210-216 (Pubitemid 23215837)
6. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6: 1-9 (Pubitemid 10103009)
7. Broadbent AM, Hruby G, Tin MM, Jackson M, Firth I (2004) Survival following whole brain radiation treatment for cerebral metastases: an audit of 747 patients. Radiother Oncol 71: 259-265 (Pubitemid 38686662)
8. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P (2005) Isolated central nervous system metastases in patients with Her2-overexpressing breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16: 1772-1777 (Pubitemid 41631239)
9. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine vs capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112: 533-543
10. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91: 639-643 (Pubitemid 39141617)
11. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19: 1242-1248 (Pubitemid 351911952)
12. Engel J, EcKel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, Dirschedl P, Hoelzel D (2003) Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55: 1186-1195 (Pubitemid 36338283)
13. Evans A, James J, Cornford E, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J, Cheung KL (2004) Brain metastases from breast cancer: identification of a high risk group. Clin Oncol 16: 345-349 (Pubitemid 38967255)
14. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743 (Pubitemid 46021510)
15. Kirsch DG, Ledezma CJ, Mathews CS, Bhan AK, Ancukiewicz M, Hochberg FH, Loeffler JS (2005) Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 23: 2114-2116 (Pubitemid 46211402)
16. Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, Kim SB, Kim WK (2008) Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 111: 523-530
17. Lentzsch S, Reichardt P, Weber F, Budach V, Dörken B (1999) Brain metastases in breast cancer: prognostic factors and management. Eur J Cancer 35: 580-585 (Pubitemid 29192966)
18. Lin N, Bellon J, Winer E (2004) CNS metastases in breast cancer. J Clin Oncol 22: 3608-3617 (Pubitemid 41103668)
19. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993-1999
20. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15: 1452-1459
21. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13: 1648-1655 (Pubitemid 46952930)
22. Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J (2001) Adjuvant treatment of brain metastases. Semin Surg Oncol 20: 50-56 (Pubitemid 32319333)
23. Lower EE, Dosick DR, Blau R, Brennan L, Danneman W, Hawley DK (2003) Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4: 114-119 (Pubitemid 36939417)
24. Lutterbach J, Bartelt S, Stancu E, Guttenberger R (2002) Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. Radiother Oncol 263: 399-405
25. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crino L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22: 625-630
26. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, Sledge Jr GW (2003) Occult central nervous system involvement in patients with metastatic breast cancer prevalence, predictive factors and impact on overall survival. Ann Oncol 14: 1072-1077 (Pubitemid 36950171)
27. Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee J-I, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im Y-H (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100: 894-900
28. Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18: 2349-2351
29. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A, International Breast Cancer Study Group (IBCSG) (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 17: 935-944 (Pubitemid 43778983)
30. Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58: 832-839 (Pubitemid 16035278)
31. Shmueli E, Wigler N, Inbar M (2004) Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40: 379-382 (Pubitemid 38121275)
32. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C, Spielmann M (2004) Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15: 1640-1644 (Pubitemid 39562604)
33. Stemmler HJ, Heinemann V (2008) Central nervous system metastases in Her2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13: 739-750
34. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impaired blood-brain barrier. Anticancer Drugs 18: 23-28 (Pubitemid 44949792)
35. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107: 696-704 (Pubitemid 44232661)
36. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment if her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7: 153
37. Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 27: 1999-2006
38. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167: 913-920 (Pubitemid 41416243)
39. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, Johnston SR, O'Brien ME, Smith IE (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45: 196-201